Family Firm Inc. Invests $33,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, Holdings Channel.com reports. The fund acquired 31 shares of the biopharmaceutical company’s stock, valued at approximately $33,000.

Several other large investors have also recently added to or reduced their stakes in the stock. West Paces Advisors Inc. grew its stake in Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares in the last quarter. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $28,000. Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. BOK Financial Private Wealth Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $37,000. Finally, Partnership Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $55,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares in the company, valued at approximately $18,941,329.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders have sold 17,731 shares of company stock worth $18,230,142 over the last three months. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $11.46 during mid-day trading on Friday, reaching $1,199.12. The company’s stock had a trading volume of 352,601 shares, compared to its average volume of 470,701. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm’s 50-day moving average is $1,088.06 and its two-hundred day moving average is $1,003.58. Regeneron Pharmaceuticals, Inc. has a 1-year low of $769.19 and a 1-year high of $1,203.49. The company has a market cap of $132.13 billion, a P/E ratio of 35.42, a PEG ratio of 3.12 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the previous year, the business earned $8.79 earnings per share. The company’s quarterly revenue was up 12.3% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Wells Fargo & Company raised their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Truist Financial reiterated a “buy” rating and issued a $1,200.00 target price (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Finally, Royal Bank of Canada upped their price target on shares of Regeneron Pharmaceuticals from $1,232.00 to $1,240.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $1,108.45.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.